ENOVIS CORP (ENOV) Stock Fundamental Analysis
USA - NYSE:ENOV - US1940141062 - Common Stock
29.73 USD
+0.04 (+0.13%)
29.73 USD
0 (0%)
Overall ENOV gets a fundamental rating of 4 out of 10. We evaluated ENOV against 191 industry peers in the Health Care Equipment & Supplies industry. ENOV may be in some trouble as it scores bad on both profitability and health. ENOV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ENOV was profitable.
In the past year ENOV had a positive cash flow from operations.
In multiple years ENOV reported negative net income over the last 5 years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV has a Return On Assets of -16.48%. This is comparable to the rest of the industry: ENOV outperforms 53.93% of its industry peers.
ENOV has a Return On Equity of -32.10%. This is comparable to the rest of the industry: ENOV outperforms 53.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENOV's Operating Margin has declined in the last couple of years.
ENOV has a Gross Margin (56.32%) which is comparable to the rest of the industry.
ENOV's Gross Margin has improved in the last couple of years.
ENOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENOV has more shares outstanding
Compared to 5 years ago, ENOV has more shares outstanding
The debt/assets ratio for ENOV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.92, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.92, ENOV perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
ENOV has a Debt/Equity ratio of 0.53. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
ENOV has a Debt to Equity ratio (0.53) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.92 |
ROIC/WACCN/A
WACC7.26%
2.3 Liquidity
ENOV has a Current Ratio of 2.25. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a Current ratio of 2.25. This is comparable to the rest of the industry: ENOV outperforms 42.41% of its industry peers.
A Quick Ratio of 1.15 indicates that ENOV should not have too much problems paying its short term obligations.
ENOV's Quick ratio of 1.15 is on the low side compared to the rest of the industry. ENOV is outperformed by 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
ENOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.01%, which is quite impressive.
Measured over the past years, ENOV shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.18% on average per year.
The Revenue has grown by 14.40% in the past year. This is quite good.
The Revenue has been decreasing by -8.73% on average over the past years.
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
3.2 Future
The Earnings Per Share is expected to grow by 23.19% on average over the next years. This is a very strong growth
ENOV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.87% yearly.
EPS Next Y12.61%
EPS Next 2Y12.05%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.98, the valuation of ENOV can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 93.19% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.34. ENOV is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.37 indicates a reasonable valuation of ENOV.
ENOV's Price/Forward Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 96.34% of the companies in the same industry.
ENOV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 8.37 |
4.2 Price Multiples
87.43% of the companies in the same industry are more expensive than ENOV, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.78 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENOV's earnings are expected to grow with 13.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.71
PEG (5Y)N/A
EPS Next 2Y12.05%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
29.73
+0.04 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners121.31%
Inst Owner Change-0.01%
Ins Owners1.19%
Ins Owner Change7.81%
Market Cap1.70B
Analysts83.53
Price Target55.42 (86.41%)
Short Float %12.32%
Short Ratio6.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.28%
Min EPS beat(2)6.8%
Max EPS beat(2)7.76%
EPS beat(4)4
Avg EPS beat(4)8.94%
Min EPS beat(4)4.97%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)5.78%
EPS beat(12)12
Avg EPS beat(12)8.75%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.21%
Revenue beat(8)2
Avg Revenue beat(8)-0.97%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-8.66%
PT rev (1m)0%
PT rev (3m)-7.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.5%
EPS NY rev (1m)0%
EPS NY rev (3m)2.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 8.37 | ||
| P/S | 0.78 | ||
| P/FCF | N/A | ||
| P/OCF | 9.04 | ||
| P/B | 0.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.78 |
EPS(TTM)3.31
EY11.13%
EPS(NY)3.55
Fwd EY11.95%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)3.29
OCFY11.07%
SpS38.31
BVpS45.1
TBVpS-9.54
PEG (NY)0.71
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 66.53% | ||
| Cap/Sales | 8.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 0.92 |
F-Score3
WACC7.26%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
EPS Next Y12.61%
EPS Next 2Y12.05%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-155.23%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year74.87%
EBIT Next 3Y29.81%
EBIT Next 5Y28.11%
FCF growth 1Y96.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y889.17%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%